
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD drug manufacturer Verona Pharma for $10 billion, adding yet another potential blockbuster to its expanding collection of post-Keytruda assets.
The Verona Deal: What Merck Gets
Verona Pharma's most valuable asset is Ohtuvayre, an inhaled medication for chronic obstructive pulmonary disease that received FDA approval in June 2024. With anticipated peak annual sales of $4 billion, the drug is a significant addition to Merck's revenue diversification strategy. This acquisition was expected given our earlier analysis underscoring Merck's urgent need to address the Keytruda patent cliff set for 2028. Additionally, see – ProKidney: What's Happening With PROK Stock?
The Math Still Doesn't Add Up
Although this acquisition signifies progress, it's evidently insufficient to resolve Merck's fundamental issue. The company anticipates a potential $15-20 billion decline in Keytruda's sales as biosimilar competition enters the market. Even if Ohtuvayre achieves its peak sales forecast, this acquisition is expected to generate only $3-4 billion in annual revenue contributions, covering roughly 20% of the anticipated Keytruda decline.
The Bigger Picture
This deal aligns with Merck's broader diversification strategy, which incorporates the promising Winrevair for pulmonary arterial hypertension and a robust pipeline of 20 potential blockbuster drugs with a combined potential of $50 billion. The company has shown its readiness to invest capital aggressively, following prior acquisitions such as the $11.5 billion Acceleron purchase and the $680 million Harpoon Therapeutics deal.
Nevertheless, the overall impact of these actions still seems inadequate to completely counterbalance the eventual decline of Keytruda. While Merck has built a solid pipeline and commenced new product launches, the timeline remains tight and the revenue gap significant.
The Investment Reality
For Merck stock to experience substantial growth, the company must assure investors that it has a thorough solution to not only mitigate the effect of Keytruda biosimilar competition but also to achieve sales growth even after the patent expiration. That level of assurance does not appear to be materializing at this time. For context, Merck stock has decreased by 16% year-to-date, lagging behind the broader S&P 500 index, which has risen by 7%, and several of its peers such as Johnson & Johnson and AbbVie, both of which have increased by 6%
The acquisition of Verona Pharma is a step forward, yet it also underscores the scale of Merck's challenge. At $10 billion for a drug with $4 billion peak sales potential, the company is investing in assets that provide only partial remedies to a significant revenue gap.
Looking Forward
Merck's acquisition strategy reflects management's understanding of the Keytruda cliff and their determination to address it. However, the company will require several more transactions of a similar scale, effective pipeline execution, and possibly some level of market expansion to completely substitute Keytruda's contribution. Until investors perceive a clearer trajectory for growth beyond 2028, Merck's valuation is likely to remain under pressure despite these strategic initiatives. For context, at its current price of around $85, MRK stock is trading at a little under 11 times its trailing adjusted earnings of $7.79 per share. This is lower than the stock's historical average price-to-earnings ratio of roughly 15 times. Of course, other factors are also influential, including slowing Gardasil sales in China. Additionally, see – Merck's Valuation Ratios.
In summary, the race against the 2028 patent cliff persists, and although Merck is putting forth significant effort, it remains uncertain whether the company can maintain its growth narrative. Merck's heavy dependence on Keytruda is a considerable concern for investors, as nearly half of the company's total sales are derived from this single product. This is precisely why sector diversification is a crucial factor we evaluate for our Trefis High Quality (HQ) portfolio. This strategic focus on achieving a balanced mix of companies across sectors has allowed the HQ portfolio to outperform the S&P 500, attaining returns exceeding 91% since its inception.
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Dr. Reddy's Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement
Dr. Reddy's Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy's Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for the global markets. Just to provide a brief overview, Keytruda® (pembrolizumab) is indicated for treating numerous cancer types. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. This collaboration combines Dr. Reddy's Laboratories Limited (NYSE:RDY)'s and Alvotech's proven capabilities in biosimilars, which will help speed up the development process and extend the global reach for the biosimilar candidate. Dr. Reddy's Laboratories Limited (NYSE:RDY)'s top management believes that the collaboration reflects its ability to develop and manufacture high-quality and affordable treatment options. Furthermore, oncology remains a top focus therapy area, and this collaboration is expected to further enhance its capabilities in oncology, with pembrolizumab representing one of the most critical therapies in immuno-oncology. Dr. Reddy's Laboratories Limited (NYSE:RDY) reported its financial results for the quarter and year ended March 31, 2025. It saw double-digit growth across its businesses, thanks to the successful product launches, higher revenues from key products in the US, and the integration of the acquired NRT business. Its FY 2025 consolidated revenues came in at INR325.5 billion, reflecting YoY growth of 17%. Its underlying revenue growth, excluding NRT business, stood at 12% YoY. Headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited (NYSE:RDY) operates as an integrated pharmaceutical company. While we acknowledge the potential of RDY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio


Forbes
3 hours ago
- Forbes
Buy AMZN Stock At $230?
Photo by Smith Collection/Gado/Getty Images (NASDAQ:AMZN) stock has increased by 4% this year, trailing the S&P 500's 7% growth slightly. This modest underperformance primarily results from a mix of valuation apprehensions and the company's significant investment cycle. Having invested $53 billion into capital expenditures in 2023 and $83 billion in 2024, Amazon is now forecasting a substantial $100 billion expenditure this year, mainly aimed at enhancing its AI capabilities. While these considerable investments may affect short-term profitability, they are essential for Amazon's long-term growth and competitive advantage. At present, with AMZN trading at $230, the crucial question for investors is straightforward: should you buy, sell, or hold? We believe there is further upside potential for AMZN stock from its current levels. Our conclusion is based on an analysis of AMZN's current valuation in relation to its recent operational performance and its current and historical financial status. Our thorough evaluation of across key metrics—Growth, Profitability, Financial Stability, and Downturn Resilience—indicates a company with robust operational performance and a solid financial base, as elaborated further below. However, if you are looking for upside potential with lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and yielded returns over 91% since its launch. Additionally, see – Block Inc.: What's Happening With XYZ Stock? How Does Valuation Look vs. The S&P 500? Based on what is paid per dollar of sales or profit, AMZN stock appears costly in comparison to the broader market. How Have Revenues Grown Over Recent Years? Revenues have experienced significant growth in recent years. How Profitable Is The profit margins of are lower than those of most companies in the Trefis coverage universe. Does Look Financially Stable? balance sheet appears robust. How Resilient Is AMZN Stock During A Downturn? AMZN stock has experienced an effect that was marginally better than the S&P 500 benchmark during one of the two recent downturns. Concerned about the effect of a market crash on AMZN stock? Our dashboard How Low Can Stock Go In A Market Crash provides a detailed analysis of the stock's performance during and after previous market crashes. Putting All The Pieces Together: What It Means For AMZN Stock In conclusion, performance across the metrics outlined above is as follows: On the whole, has shown strong performance across key indicators. From a price-to-sales (P/S) standpoint, a ratio of 3.6 times trailing revenues, combined with low double-digit revenue growth, seems reasonable to us. While the current price-to-earnings ratio for AMZN may seem slightly elevated, we expect a more substantial growth trajectory in the upcoming years. This is largely due to the increasing impact of Amazon Web Services (AWS), its more profitable cloud computing segment, on the total revenue mix. Related – Amazon Stock: Path To 2x Growth. Considering these aspects, we believe there is still significant upside potential for AMZN stock from its current position. Naturally, our evaluation might be incorrect. Investors may be reluctant to assign a higher valuation multiple, especially given Amazon's considerable capital expenses, increasing competition, and slower-than-anticipated growth in certain business segments. However, if you are working with a 3-5 year investment horizon, AMZN stock could be a beneficial addition to your investment portfolio. While it appears there is further upside to AMZN stock, consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to deliver strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks offers a responsive method to capitalize on favorable market conditions while minimizing losses when markets decline, as explained in RV Portfolio performance metrics.


USA Today
4 hours ago
- USA Today
NFL analyst predicts where Kyren Williams' new contract should rank among other RBs
Kyren Williams and the Los Angeles Rams are engaged in contract extension negotiations this offseason as the running back enters his fourth NFL season. If the two sides agree on a deal, Williams will undoubtedly become one of the highest-paid running backs in the NFL. Bleacher Report's Moe Moton predicts that when ink hits paper, Williams will be the fifth-highest paid running back in the league with a new three-year, $40.5 million contract with $25.5 million guaranteed. Kyren Williams should slightly edge [Buffalo Bills running back] James Cook in salary. As of Tuesday, the Los Angeles Rams seem more willing to strike a new deal with him than the Buffalo Bills are with Cook. ... Williams is more vital to the Rams' offense than Cook is to the Bills' Josh Allen-led offense. Moton added that Matthew Stafford's age and impending departure (in a year or two, at least) mean that the Rams will need to lean on veteran leadership at other positions — including running back — in the future. Sean McVay can't rely on Blake Corum or Jarquez Hunter to carry the load if Williams leaves and Stafford's production declines, so the only way forward, really, is to keep Williams around on a lucrative contract extension. It makes sense, especially given Williams' consistent production over the past two years. And while paying lots of money to a running back who isn't a name like Barkley, Henry or McCaffrey might be hard to swallow, the Rams are trying to build a long-term contender. Williams will have to be a part of that with the quarterback plan still an unknown post-Stafford.